- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Elacestrant: Treatment Considerations, Including Dosing and Compliance
Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.
EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer
EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles
EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer
EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance
EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer
EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones explores considerations for using oral selective estrogen receptor degraders (SERDs) with Callahan, Vidal, and Gradishar. Callahan highlights patients for whom she wouldn’t consider oral SERDs, emphasizing the need for alternatives in visceral crisis situations. Vidal discusses the recommended dose schedule, dose modifications, and potential adherence concerns, noting the convenience of oral therapy despite adherence challenges. Gradishar emphasizes the continuous and individualized treatment duration, which continues for as long as the patient responds and tolerates the therapy. Callahan sheds light on determining treatment failure, emphasizing the importance of definitive disease progression rather than relying solely on liquid biopsy results. The discussion provides insights into patient selection, dosing considerations, adherence challenges, and duration of treatment with oral SERDs, offering practical guidance for clinicians.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML
August 16th 2025Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Read More
